Suzetrigine is under investigation in clinical trial NCT05558410 (Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty). Suzetrigine is an oral, selective sodium channel blocker and non-opioid analgesic that is used to treat moderate or severe pain. Suzetrigine is typically given for only a few days and has not been linked to elevations in serum aminotransferase or alkaline phosphatase levels during therapy or to episodes of clinically apparent liver injury. Its therapeutic use is listed as analgesics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include JOURNAVX, VX-548, Suzetrigina and VX548. Its PubChem CID is 156445116.
Suzetrigine
| CAS No | 2649467-58-1 |
|---|---|
| Molecular Formula | C21H20F5N3O4 |
| Molecular Weight | 473.4 g/mol |
| Synonyms | 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Suzetrigine is under investigation in clinical trial NCT05558410 (Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty). Suzetrigine is an oral, selective sodium channel blocker and non-opioid analgesic that is used to treat moderate or severe pain.
The listed CAS number is 2649467-58-1.
The listed molecular formula is C21H20F5N3O4.
The listed molecular weight is 473.4 g/mol.
4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide.
The source lists JOURNAVX, VX-548, Suzetrigina and VX548.